Stada Arzneimittel AGSAZX.N:GER

30.42
0.045 / 0.15%
270.52k
18.18%
0.9626
Close in EURToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Sep 02 2014 16:35 BST.

Summary

On Tuesday, Stada Arzneimittel AG (SAZX.N:GER) closed at 30.42, 9.01% above its 52-week low of 27.90, set on Aug 08, 2014.

52-week range
Today
27.90
Aug 08 2014
42.50
Oct 31 2013
Markit short selling activity
Low
Medium
High
Open30.47
Day high30.64
Day low30.07
Bid30.41
Offer30.51
Previous close30.37
Average volume209.46k
Shares outstanding60.47m
Free float60.47m
P/E (TTM)15.44
Market cap1.84bn EUR
EPS (TTM)1.97 EUR
Annual div (TTM)0.4859 EUR
Annual div yield (TTM)1.60%
Div ex-dateJun 05 2014
Div pay-dateJun 05 2014
Data delayed at least 15 minutes, as of Sep 02 2014 16:35 BST.

Comparative analysis

Past 90 days
1 week1 month6 months1 year5 years
Stada Arzneimittel AG+0.26%-1.46%-17.10%-18.18%+95.97%
DEUTSCHE BORSE DAX INDEX-0.85%+3.22%-0.86%+15.32%+78.71%
DE/HEALTH CARE-0.05%+5.57%+1.17%+16.14%--
DE/PHARMACEUTICALS-0.15%+6.46%+0.18%+16.20%--
Data delayed at least 15 minutes, as of Sep 02 2014 16:35 BST.
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.

Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.